Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

6,363

datasets available to search

ShareScore release 0.7.1

Reset

Dataset results

6,363 results for “Mutations”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov40/100

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

ClinicalTrials.gov study NCT01610336. IPD Sharing: YES. Countries: 14. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

ClinicalTrials.gov study NCT02906020. IPD Sharing: YES. Countries: 16. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

ClinicalTrials.gov study NCT01682083. IPD Sharing: YES. Countries: 25. Publications: 9.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

ClinicalTrials.gov study NCT04619004. IPD Sharing: YES. Countries: 16. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov study NCT04644237. IPD Sharing: YES. Countries: 10. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

ClinicalTrials.gov study NCT02083354. IPD Sharing: UNDECIDED. Countries: 5. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov40/100

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

ClinicalTrials.gov study NCT02684058. IPD Sharing: YES. Countries: 20. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thy

ClinicalTrials.gov study NCT04940052. IPD Sharing: YES. Countries: 11. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

ClinicalTrials.gov study NCT02394795. IPD Sharing: YES. Countries: 1. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

ClinicalTrials.gov study NCT03505710. IPD Sharing: YES. Countries: 5. Publications: 3.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-20

ClinicalTrials.gov study NCT03822117. IPD Sharing: YES. Countries: 11. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

ClinicalTrials.gov study NCT04171700. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

ClinicalTrials.gov study NCT04729387. IPD Sharing: YES. Countries: 26. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

ClinicalTrials.gov study NCT01953926. IPD Sharing: YES. Countries: 13. Publications: 10.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

ClinicalTrials.gov study NCT02034110. IPD Sharing: YES. Countries: 14. Publications: 8.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

ClinicalTrials.gov study NCT03512197. IPD Sharing: YES. Countries: 20. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov40/100

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

ClinicalTrials.gov study NCT02335944. IPD Sharing: YES. Countries: 11. Publications: 2.

controlledIPD-YESFeb 2026View details →
dryad40/100

Data from: The pathogenic E139D mutation stabilizes a non-canonical active state of the multi-domain phosphatase SHP2

Open the record for dataset details and reuse information.

publicJul 2025View details →
dryad40/100

Data from: The role of mutation bias in adaptive molecular evolution: insights from convergent changes in protein function

Open the record for dataset details and reuse information.

publicNov 2023View details →
dryad40/100

Data from: Gene network topology drives the mutational landscape of gene expression

Open the record for dataset details and reuse information.

publicJul 2025View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record